OOIR: Observatory of International Research

Papers

(The TQCC of Biomarker Research is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	149
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	144
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	124
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	121
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	115
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	106
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	99
Mitochondrial transfer in hematological malignancies	97
Advances in the DNA methylation hydroxylase TET1	96
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	96
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	90
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	87
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	85
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	79
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	76
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	71
p53 biology and reactivation for improved therapy in MDS and AML	67
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	61
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	59
Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC	58
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	57
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	54
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	54
Donor T cells for CAR T cell therapy	53
Unveiling the potential of CLL-1: a promising target for AML therapy	52

The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	50
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	47
Targeting interleukin-1β and inflammation in lung cancer	47
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	47
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	46
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	45
The role and metabolic adaptations of neutrophils in premetastatic niches	45
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	45
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	43
The role of BATF in immune cell differentiation and autoimmune diseases	42
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	42
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	42
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	41
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	41
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	40
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	40
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	40
Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions	39
BRD4: an effective target for organ fibrosis	39
Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia/lymphoma	39
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	38
Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas	38
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	37
Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis	37
Correction: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	36
Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected	36
Nucleases as molecular targets for cancer diagnosis	35
Comparison of proton therapy and photon therapy for early-stage non-small cell lung cancer: a meta-analysis	35
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	33
Updates on CAR T cell therapy in multiple myeloma	33
The lncRNA TEX41 is upregulated in pediatric B-Cells Acute Lymphoblastic Leukemia and it is necessary for leukemic cell growth	32
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	32
Correction: Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	32
The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study	31
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	31
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	31
Intratumor microbiome in cancer progression: current developments, challenges and future trends	31
Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia	30
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors	30
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	30
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer	29
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer	28
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer	28
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients	28
The importance of critically short telomere in myelodysplastic syndrome	28
Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes	27
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer	27
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	27
Analyzing PKC Gamma (+ 19,506 A/G) polymorphism as a promising genetic marker for HCV-induced hepatocellular carcinoma	27
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	26

Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	25
Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy	25
Single-cell RNA sequencing identifies a subtype of FN1 + tumor-associated macrophages associated with glioma recurrence and as a biomarker for immunotherapy	25
FGL1 and FGL2: emerging regulators of liver health and disease	24
NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer	24
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	24
Tobacco smoking associates with NF1 mutations exacerbating survival outcomes in gliomas	24
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	24
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples	24
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma	24
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	23
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives	23
Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma	23
New cell sources for CAR-based immunotherapy	23
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics	23
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification	22
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs	22
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool	22
E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors	21
Association between circulating ECM-associated molecules and cardiovascular outcomes in hemodialysis patients: a multicenter prospective cohort study	21
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer	21
Application of double-negative T cells in haematological malignancies: recent progress and future directions	20
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	20
Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia	20
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States	20
Correction: CRISPR/Cas-based CAR-T cells: production and application	19
MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage	19
SRTdb: an omnibus for human tissue and cancer-specific RNA transcripts	19
Human induced-T-to-natural killer cells have potent anti-tumour activities	19
Single-cell multi-omics analysis identifies SPP1+ macrophages as key drivers of ferroptosis-mediated fibrosis in ligamentum flavum hypertrophy	19
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases	18
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer	18
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies	18
Targeting TIGIT for cancer immunotherapy: recent advances and future directions	18
The significant others of aurora kinase a in cancer: combination is the key	17
MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression	17
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer	17
A germline FLT3 variant in aplastic anemia	17
Long noncoding RNA LIPH-4 promotes esophageal squamous cell carcinoma progression by regulating the miR-216b/IGF2BP2 axis	17
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals	16
Toll-like receptor 3: a double-edged sword	16
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response	16
Cervical cancer heterogeneity: a constant battle against viruses and drugs	16
The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer	16
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted	16
PCSK9 in T-cell function and the immune response	16
Ribosome profiling: a powerful tool in oncological research	16
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma	16
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications	16
Oncogenic alterations in advanced NSCLC: a molecular super-highway	16